In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Colgate on acquisitions

This article was originally published in The Rose Sheet

Executive Summary

Colgate-Palmolive would "not easily move into" OTC or pharmaceutical categories, CEO Reuben Mark states during June 1 Sanford Bernstein Strategic Decisions Conference. Colgate has been identified as a potential bidder for Pfizer's Consumer Healthcare unit, which in addition to OTCs includes the Listerine oral care brand (1"The Rose Sheet" May 29, 2006, p. 4). Pfizer has expressed it is not interested in selling its brands individually. Separately, Mark notes the firm's advertising spend will be up a record 13%-14% in 2006. Colgate spent $297.1 mil. behind its global brands in the first quarter (2"The Rose Sheet" March 14, 2006, p. 4). The company also placed a record amount behind advertising last year, with spending up 11.5%, exec notes...

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts